{
    "paper_id": "73ab2c5ff83b9e257e8810fb0000f406f42bcf3d",
    "metadata": {
        "title": "",
        "authors": []
    },
    "abstract": [],
    "body_text": [
        {
            "text": "Durante la actual pandemia por el virus SARS CoV-2, se est\u00e1 utilizando un amplio arsenal terap\u00e9utico que incluye medicamentos de uso infrecuente, por ello es importante conocer sus posibles efectos adversos. Presentamos el caso de un paciente ingresado por infecci\u00f3n respiratoria por COVID-19, que present\u00f3 en su evoluci\u00f3n cl\u00ednica una perforaci\u00f3n c\u00f3lica aguda, tras ser tratado con altas dosis de corticoides y con tocilizumab. Se han comunicado caso cl\u00ednicos similares en pacientes con administraci\u00f3n de tocilizumab y enfermedades autoinmunes, si bien la informaci\u00f3n relacionando perforaciones intestinales e infecci\u00f3n por COVID-19 es muy escasa. Por otro lado, dado que el espectro cl\u00ednico del virus es aparentemente amplio (1) , la posibilidad de que sea la \u00fanica causa subyacente no puede ser del todo descartada. Se trata de un var\u00f3n de 66 a\u00f1os, con s\u00edndrome metab\u00f3lico como \u00fanico antecedente de inter\u00e9s y sin tratamiento habitual; en el contexto de un cuadro de insuficiencia respiratoria aguda secundaria a COVID 19, present\u00f3 dolor abdominal con defensa y aumento de leucocitosis y de PCR asociado. Tras la realizaci\u00f3n de una TC abdominop\u00e9lvica se identifica abundante neumoperitoneo secundario a perforaci\u00f3n de colon derecho. Se realiz\u00f3 una colectom\u00eda derecha, no observando signos de isquemia, ni divert\u00edculos en la pieza extra\u00edda. Anteriormente hab\u00eda recibido tratamiento con metilprednisolona 100mg/d\u00eda (durante 5 d\u00edas), tocilizumab (dosis \u00fanica de 600mg, correspondiente a 8mg/kg) y 15 d\u00edas previos a la intervenci\u00f3n, azitromicina, hidroxicloroquina y lopinavir/ritonavir. La biopsia revela un \u00e1rea de necrosis con ulceraci\u00f3n de la mucosa de 12mm en cara anterior del ciego, sin signos de malignidad ni otras \u00e1reas de isquemia. El tocilizumab es un anticuerpo monoclonal humanizado que bloquea tanto los receptores solubles como de membrana de interleukina 6, inhibiendo as\u00ed la cascada inflamatoria generada por dicho mediador, y se emplea de forma habitual en enfermedades autoinmunes como parte del grupo de f\u00e1rmacos biol\u00f3gicos modificadores de enfermedad. Este f\u00e1rmaco no ha sido todav\u00eda aprobado por la Food and Drug Administration para tratar la neumon\u00eda por COVID-19, sin embargo, su uso en casos graves se ha generalizado en el contexto de la pandemia. Su seguridad fue evaluada en el ensayo cl\u00ednico LITHE (2) . En \u00e9l las complicaciones gastrointestinales graves se describieron como infrecuentes, y aparecieron en los pacientes en tratamiento concurrente con corticosteroides o AINEs. Sin embargo, diversos estudios se\u00f1alan mayor riesgo de perforaci\u00f3n intestinal baja en pacientes en tratamiento con tocilizumab (3)(4)(5) , habi\u00e9ndose descrito una incidencia cercana a 2/1000 paciente-a\u00f1o en los que se ha administrado al menos una dosis de tocilizumab (6) , especialmente cuando \u00e9sta es de 8mg/kg frente a 4mg/kg (7) . Del mismo modo, el riesgo de perforaci\u00f3n intestinal es mayor en comparaci\u00f3n con el resto de f\u00e1rmacos biol\u00f3gicos moduladores de enfermedad (3)(4)(8) (9) . Estas perforaciones aparecen en los primeros 12 meses tras el tratamiento y no se incrementan con el tiempo (5) (9) , siendo siempre m\u00e1s frecuentes en los pacientes que han recibido corticoides (5) (6) . Una posible",
            "cite_spans": [
                {
                    "start": 726,
                    "end": 729,
                    "text": "(1)",
                    "ref_id": "BIBREF2"
                },
                {
                    "start": 2325,
                    "end": 2328,
                    "text": "(2)",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 2773,
                    "end": 2776,
                    "text": "(6)",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 2834,
                    "end": 2837,
                    "text": "(7)",
                    "ref_id": "BIBREF8"
                },
                {
                    "start": 2988,
                    "end": 2991,
                    "text": "(9)",
                    "ref_id": "BIBREF10"
                },
                {
                    "start": 3102,
                    "end": 3105,
                    "text": "(5)",
                    "ref_id": "BIBREF6"
                },
                {
                    "start": 3106,
                    "end": 3109,
                    "text": "(9)",
                    "ref_id": "BIBREF10"
                },
                {
                    "start": 3188,
                    "end": 3191,
                    "text": "(5)",
                    "ref_id": "BIBREF6"
                },
                {
                    "start": 3192,
                    "end": 3195,
                    "text": "(6)",
                    "ref_id": "BIBREF7"
                }
            ],
            "ref_spans": [],
            "section": ""
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "podr\u00eda ser el papel en la funci\u00f3n de barrera intestinal de la IL-6 (3) as\u00ed como una menor intensidad en la respuesta inflamatoria inmediata",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "se\u00f1alar que la mortalidad tras perforaci\u00f3n en estos casos puede llegar al 46% (3) , hecho que agravar\u00eda notablemente el pron\u00f3stico, ya de por s\u00ed incierto",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Finalmente",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "American Journal of Emergency Medicine Abdominal and testicular pain : An atypical presentation of COVID-19",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Kim",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Thomsen",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Sell",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "J"
                    ],
                    "last": "Goldsmith",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Am J Emerg Med",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "Tocilizumab Inhibits Structural Joint Damage in Rheumatoid Arthritis Patients With Inadequate Responses to Methotrexate Results From the Double-Blind Treatment Phase of a Randomized Placebo-Controlled Trial of Tocilizumab Safety and Prevention of Structur",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "M"
                    ],
                    "last": "Kremer",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Blanco",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Brzosko",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Burgos-Vargas",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Halland",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Vernon",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "ARTHRITIS Rheum",
            "volume": "63",
            "issn": "3",
            "pages": "609--630",
            "other_ids": {}
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Strangfeld",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Richter",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Siegmund",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Herzer",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Rockwitz",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Demary",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "Ann Rheum Dis",
            "volume": "76",
            "issn": "",
            "pages": "504--514",
            "other_ids": {}
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "Risk for Gastrointestinal Perforation among Rheumatoid Arthritis Patients receiving Tofacitinib, Tocilizumab, or other Biologics",
            "authors": [
                {
                    "first": "F",
                    "middle": [],
                    "last": "Xie",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Yun",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Bernatsky",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "R"
                    ],
                    "last": "Curtis",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Arthritis Rheumatol",
            "volume": "68",
            "issn": "11",
            "pages": "2612--2619",
            "other_ids": {}
        },
        "BIBREF6": {
            "ref_id": "b6",
            "title": "Longterm Safety of Tocilizumab : Results from 3 Years of Followup Postmarketing Surveillance of 5573 Patients with Rheumatoid Arthritis in Longterm Safety of Tocilizumab : Results from 3 Years of Followup Postmarketing Surveillance of 5573 Patients with R",
            "authors": [
                {
                    "first": "K",
                    "middle": [],
                    "last": "Yamamoto",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Goto",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Hirao",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Nakajima",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Origasa",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "J Rheumatol",
            "volume": "",
            "issn": "8",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF7": {
            "ref_id": "b7",
            "title": "Integrated safety in tocilizumab clinical trials",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "H"
                    ],
                    "last": "Schiff",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "M"
                    ],
                    "last": "Kremer",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Jahreis",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Vernon",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "D"
                    ],
                    "last": "Isaacs",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "F"
                    ],
                    "last": "Vollenhoven",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Van",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Arthritis Res Ther",
            "volume": "13",
            "issn": "5",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF8": {
            "ref_id": "b8",
            "title": "IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to antitumour necrosis factor biologicals : results from a 24-week multicentre randomised placebo-controlled trial",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Emery",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Keystone",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [
                        "P"
                    ],
                    "last": "Tony",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Cantagrel",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Vollenhoven",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Van",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Sanchez",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "Ann Rheum Dis",
            "volume": "",
            "issn": "",
            "pages": "6--13",
            "other_ids": {}
        },
        "BIBREF9": {
            "ref_id": "b9",
            "title": "Safety of synthetic and biological DMARDs : a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Sepriano",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Kerschbaumer",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "S"
                    ],
                    "last": "Smolen",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Heijde D Van Der",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Dougados",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Vollenhoven",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Van",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Ann Rheum Dis",
            "volume": "",
            "issn": "",
            "pages": "1--11",
            "other_ids": {}
        },
        "BIBREF10": {
            "ref_id": "b10",
            "title": "Incidence of Gastrointestinal Perforations in Patients with Rheumatoid Arthritis Treated with Tocilizumab from Clinical Trial , Postmarketing , and Real-World Data Sources",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Monemi",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Berber",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Sarsour",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Rheumatol Ther",
            "volume": "3",
            "issn": "2",
            "pages": "337--52",
            "other_ids": {}
        }
    },
    "ref_entries": {},
    "back_matter": []
}